Gemcitabine

Drug Profile

Gemcitabine

Alternative Names: dFdC; dFdCTP; Gemtro; Gemzar; LY 188011

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly; University of Innsbruck
  • Developer Eli Lilly
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer; Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Phase III Cervical cancer
  • Phase II Lymphoma; Renal cell carcinoma
  • Phase I Head and neck cancer

Most Recent Events

  • 01 May 2016 Eli Lilly completes a phase II trial in Renal cell carcinoma (Combination therapy, Metastatic disease) in USA (IV-infusion) (NCT00496587)
  • 30 May 2015 Gemcitabine is still in phase II trials for Renal cell carcinoma (Combination therapy, Metastatic disease) in the USA
  • 30 May 2015 Gemcitabine is still in phase III trials for Cervical cancer in Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top